EMEA, FDA Nearly Equal In Mean Approval Times, But FDA Is Faster – Study
Executive Summary
While the mean approval times for the European Medicines Agency and FDA have been "nearly identical" for products approved in recent years, FDA has cleared a greater number of products faster than the EMEA, according to a study by the Tufts Center for the Study of Drug Development
You may also be interested in...
Corticosteroid Studies Assessing Growth Effects Should Not Start Before Age 3
FDA's final guidance on studying the effects of inhaled and intranasal corticosteroids on growth in children narrows the recommended lower age limit for patients to three years of age
Rx Importation Legislation Debate Begins Anew, But Battle Lines Are Familiar
Sens. Byron Dorgan, D-S.D., and Olympia Snowe, R-Maine, are trying to build momentum for their proposal to allow prescription drug importation, vowing at a March 7 hearing that they will push to bring the measure quickly to the Senate floor
FDA Calls For Third-Party Auditor To Rectify Actavis Manufacturing Problems
FDA is recommending that Actavis "promptly initiate" a third-party audit program to oversee the correction of manufacturing discrepancies at the firm's Little Falls, N.J. facility, following the second warning letter for the plant in less than five months